Not provided
Not provided
Not provided
Not provided
Not provided
Lack of Funding from Sponsor
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Avadim Technologies, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Participation will be for approximately 21 days (3 study visits,1 week apart with allowance for scheduling conflicts). A topical (or placebo) foam alone or with a splint will be used. Demographic and symptom information will be obtained. At each visit 3 questionnaires (BCT, CTS-6, and DASH) will be completed and an ultrasound of the wrist (median nerve) will be done to document any change in symptoms and/or in the size of the nerve. Random assignment will be to one of 4 groups: foam or placebo with or without a night splint. We will provide instruction on how to apply the foam, whether or not and how to wear the splint, and return visits.
The PI will identify potential participants from his clinical practice. Evaluation of symptoms will be by exam, questionnaires, and ultrasound of the median nerve. These will document baseline/change in the size of the median nerve and improvement in function/symptoms. The questionnaires are 1.) Boston Carpal Tunnel (BCT). 2.) Carpal Tunnel-6 (CTS-6); and 3.) Disabilities of the Arm, Shoulder and Hand (DASH). These will be used to document a baseline and change (if any) in nerve size and hand symptoms, over a 2 week time frame, that are common in carpal tunnel syndrome (including numbness, pain, tingling, and/or decreased function).
Treatment groups are as follows:1.) Theraworx foam alone; 2.) Theraworx foam with night time splint; 3.) Placebo foam alone; 4.) Placebo foam with night time splint. The active ingredient in Theraworx foam is magnesium sulfate and will not be in the placebo foam. Instructions on how to apply the foam, whether or not and how to wear the splint, and return visits will be provided. If in a group that requires night time splinting, the subject must wear the splint only at night and for a minimum of 8 hours.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1: Theraworx Foam alone | Experimental | Theraworx foam only |
|
| Arm 2: Theraworx Foam and night splint | Active Comparator | Theraworx foam with a night time splint |
|
| Arm 3: Placebo foam alone | Placebo Comparator | Placebo foam alone |
|
| Arm 4: Placebo foam and night splint | Other | Placebo foam with a night time splint |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Theraworx Foam | Drug | Apply Theraworx Foam alone |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Improvement (decrease) in size of median nerve at the wrist | Decrease in cross sectional area of median nerve as determined by ultrasound exam | 2 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Improvement (decrease) in Boston Carpal Tunnel Questionnaire (BCTQ) | Improvement in PRO as indicated by a decreased score on questionnaire indicating improved in function and decreased symptoms | 2 weeks |
| Improvement (decrease) in Carpal Tunnel 6 (CTS-6) score |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| John Fowler, MD | University of Pittsburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kaufmann Building | Pittsburgh | Pennsylvania | 15213 | United States | ||
| University of Pittsburgh Medical Center |
The ultrasound measurements and PRO questionnaire scores will be shared with the sponsor Avadim Technologies at a minimum of approximately 60 day intervals throughout the study (1 year) and at the discretion of the PI. In addition, final data will be provided within 12 months of completion of last participant
Updated at intervals of approximately 60 days (minimum) and as needed as determined by PI. Final data will be available approximately 12 months after completion of last participant and will be available for 9 to 12 months.
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002349 | Carpal Tunnel Syndrome |
| ID | Term |
|---|---|
| D020423 | Median Neuropathy |
| D020422 | Mononeuropathies |
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
Not provided
Not provided
Randomization will be to one of four groups: 1.) Theraworx foam alone; 2.) Theraworx foam plus night time splint; 3.) Placebo foam alone; 4.) Placebo foam plus night time splint.
Theraworx Foam is an FDA registered (NDC 61594-001-02) topical agent (active ingredient: magnesium sulfate superficia 6 x 0.05% HPUS) for muscle cramp and spasm relief.
Not provided
Not provided
Not provided
| Placebo Foam |
| Drug |
Apply placebo foam alone |
|
| Theraworx Foam and night splint | Other | Apply Theraworx Foam and night time splint |
|
| Placebo Foam and night time splint | Other | Apply placebo foam and night time splint |
|
Improvement in patient reported outcome (PRO) as determined by a lower CTS-6 score number than at baseline. Score ranges from 26 (worst) to 0 (best) |
| 2 weeks |
| Improvement (decrease) in Disabilities of Arm, Shoulder, Hand (DASH) score | Improvement in patient reported outcome (PRO) as determined by decreased DASH score from baseline. Score ranges from 150 (worst) to 30 (best) | 2 weeks |
| Pittsburgh |
| Pennsylvania |
| 15213 |
| United States |
| D009422 | Nervous System Diseases |
| D009408 | Nerve Compression Syndromes |
| D012090 | Cumulative Trauma Disorders |
| D013180 | Sprains and Strains |
| D014947 | Wounds and Injuries |